Despite efforts for improvement, the "State of the Air" report reveals concerns.

Published Date: 23 Apr 2023

Despite Improvement Efforts, the "State of the Air" Report Highlights Issues.

Read Full News

Latest News

Dupilumab's IL-4/IL-13 Blockade Drives Efficacy Edge in EVEREST Guy Brusselle, MD, PhD

Guy Brusselle, MD, PhD, explains why broader cytokine blockade with dupilumab outpaced omalizumab, and why nonremitters in EVEREST still improved.

Verekitug Reduces Asthma Exacerbations Up to 87%, With Michael Wechsler, MD Michael Wechsler, MD, MSc

Phase 2 VALIANT data show the anti-TSLP receptor antibody sharply reduced exacerbations in patients with high eosinophil counts.

8 Pulmonology Headlines You Missed in Q3 2026

8 Pulmonology Headlines You Missed in Q3 2026

8 Pulmonology Headlines You Missed in September 2026

8 Pulmonology Headlines You Missed in September 2026

Dupilumab Outperforms Omalizumab for Asthma Remission in Phase 4 EVEREST Guy Brusselle, MD, PhD

Guy Brusselle, MD, PhD, says that 64% of dupilumab-treated patients met composite asthma clinical remission criteria at week 24 versus 40.5% with omalizumab.

What 2 Seasons of Arexvy Data Reveal About RSV-Related Risk Reduction Ann Falsey, MD

Two-season real-world data show Arexvy reduces RSV-related MACE and COPD and asthma exacerbations in adults 60 and older, Ann Falsey, MD, says.

Todays Updates

How Dermatologists Can Sort Through Skincare and Cosmeceutical Claims

How Dermatologists Can Sort Through Skincare and Cosmeceutical Claims

Todays Updates

How Dermatologists Can Sort Through Skincare and Cosmeceutical Claims

How Dermatologists Can Sort Through Skincare and Cosmeceutical Claims

Latest News

Guy Brusselle, MD, PhD, explains why broader cytokine blockade with dupilumab outpaced omalizumab, and why nonremitters in EVEREST still improved.

Phase 2 VALIANT data show the anti-TSLP receptor antibody sharply reduced exacerbations in patients with high eosinophil counts.

8 Pulmonology Headlines You Missed in Q3 2026

8 Pulmonology Headlines You Missed in September 2026

Guy Brusselle, MD, PhD, says that 64% of dupilumab-treated patients met composite asthma clinical remission criteria at week 24 versus 40.5% with omalizumab.

Two-season real-world data show Arexvy reduces RSV-related MACE and COPD and asthma exacerbations in adults 60 and older, Ann Falsey, MD, says.

News All Time

PDGF Pathway in PAH: Setbacks and Promise, With Olivier Sitbon, MD, PhD Olivier Sitbon, MD, PhD

Olivier Sitbon, MD, PhD, reviews PDGF-targeted therapy in PAH, from imatinib's IMPRES trial to new prodrug and antibody approaches.

Dupilumab Scores on Win-Ratio Analysis in Pediatric Asthma: Sharon Dell, MD Sharon Dell, MD

Dell discusses an analysis of VOYAGE showing dupilumab more than doubled the odds of favorable asthma outcomes in children, regardless of baseline ICS dose.

BEAM-302 Base Editing Sustains Protective AAT, With John Hurst, MBBS, PhD John Hurst, MBBS, PhD

Hurst discusses data showing durably raised protective AAT levels in patients with alpha-1 antitrypsin deficiency.

STAT6 Degraders: Accessible Biologic-Like Asthma Care? With Njira Lugogo, MD Njira Lugogo, MD

Lugogo, ofUniversity of Michigan, discusses how oral STAT6 degraders like KT-621 could expand biologic-like asthma treatment beyond highest severity.

AIRCULES: Lunsekimig Benefit Scales With Severity, With Njira Lugogo, MD Njira Lugogo, MD

Phase 2b subgroup data showed lunsekimig's exacerbation benefit scaled with asthma severity and biomarker levels.

Verekitug's TSLP Mechanism and VALIANT Trial Results, With Michael Wechsler, MD Michael Wechsler, MD, MSc

Wechsler walks through verekitug's mechanism, VALIANT's design, key efficacy and safety findings, and what's next for TSLP-targeted asthma therapy.

Semaglutide Cuts Asthma Attacks by up to 40% in Real-World Study Victoria Johnson

Semaglutide was linked to fewer asthma attacks and COPD flare-ups than sulfonylureas, with no effect seen for other GLP-1 therapies.

Tozorakimab Cuts COPD Exacerbations Across Eosinophil Levels: Frank Sciurba, MD Frank C. Sciurba, MD

Sciurba, of University of Pittsburgh, discusses full phase 3 OBERON and TITANIA results, including stronger responses in current smokers.

FIBRONEER-ON: Nerandomilast's Durable IPF, PPF Safety, With Wim Wuyts, MD, PhD Wim Wuyts, MD, PhD

Wuyts, of University Hospitals Leuven discusses interim FIBRONEER-ON open-label extension data showing nerandomilast's favorable safety profile.

Dupilumab Cuts COPD Exacerbations Across Seasons, Smoking Status: Surya Bhatt, MD Surya P. Bhatt, MD

Bhatt also discusses how these findings inform the choice between dupilumab and mepolizumab under GOLD 2026.

Oral STAT6 Degraders Fill Niche in Asthma Care, With Michael Wechsler, MD Michael Wechsler, MD, MSc

Wechsler, of National Jewish Health discusses how oral STAT6 degraders like KT-621 could offer a mechanistically distinct treatment option.

Rademikibart Improves FEV1 in Phase 2 Asthma Exacerbation Trial Victoria Johnson

However, Connect Biopharma's phase 2 Seabreeze STAT Asthma trial's primary treatment-failure end point missed statistical significance.

STAT6 Degradation: A Novel Oral Target for Asthma? Victoria Johnson

At ERS 2026, pulmonologists framed oral STAT6 degradation—led by Kymera's KT-621—as a potential biologic-like, access-expanding approach.

FDA Grants Priority Review for Insmed's ARIKAYCE sNDA for MAC Lung Disease

FDA Grants Priority Review for Insmed's ARIKAYCE sNDA for MAC Lung Disease

ERS Congress 2026: 6 Late-Breaking Trials to Know Victoria Johnson

Read 6 late-breaking updates from ERS Congress 2026 that clinicians managing respiratory disease should know.

Using AI for COPD Diagnosis, Equity, Guideline Gaps: Alvar Agusti, MD, PhD

Using AI for COPD Diagnosis, Equity, Guideline Gaps: Alvar Agusti, MD, PhD

Recommended News For You

Breast Density Laws Fall Short Raising Additional Screening

Certain surgical gestures during prostate removal linked to better sexual function recovery

NEJM: Pirtobrutinib is effective in CLL patients who have received prior BTK inhibitor therapy.

Pressing the Sleep button could have a positive impact on cognition.

Promising for Monitoring and Diagnosis of AD is the finger-prick test.

Belzutifan Combo Could be Second-Line Option in Advanced RCC

Getting More Done With Less Blood.

Recommended Articles For You

How EPCORITAMAB is Revolutionizing the Treatment of Cancer 

Radiopharmaceutical Theranostics: Precision Radiation Delivered Through Molecular Targeting 

Digital Oncology Command Platforms for Longitudinal Cancer Care Coordination 

Demystifying Lymphocytes: Everything You Need to Know  

Whats more on Hidoc Dr.

Medical Updates
KOL Videos
Surveys
Events

Daily news to keep you up to date

Gain valuable insights with our in-depth KOL Video discussions

Participate and win cash vouchers

Get updates on the latest events happening around the world
Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

More evidence links physical activity with improved cancer survival

2.

Base-edited T-cell therapy offers additional hope for treating resistant leukemia.

3.

Ultrasound bras; HPV and thyroid cancer; language minimizing adverse events.

4.

In schizophrenia, sexual dysfunction is frequent.

5.

Nanoparticle vaccine prevents multiple cancers and stops metastasis in mice

1.

The Role of Calcium Corrections in Accurate Blood Test Results 

2.

Clonal Hematopoiesis and Healthy Aging: Insights, Mechanisms, and Clinical Relevance

3.

Hematopoietic Stem Cell Fitness Biomarkers: Clinical Relevance and Emerging Paradigms

4.

Cemiplimab: A Revolutionary Drug For Treating Cancer

5.

Unlocking the Potential of Hemin: A Novel Approach to Health and Wellbeing

1.

International Conference on Oncology, Cardiology and Critical Care Policy

2.

International Conference on Innovations in Critical Care for Oncology and Cardiology

3.

International Conference on Oncology, Cancer Prevention and Public Health

4.

International Conference on Cancer Nursing and Rehabilitation Strategies

5.

International Conference on Cancer Nursing and Hematology Support

1.

A Comprehensive Guide to First Line Management of ALK Positive Lung Cancer - Part II

2.

The Comprehensive Impact of CDK4/6 Inhibition in HR+/HER2- Metastatic Breast Cancer: Insights from PALOMA-2.

3.

Blood Clotting Disorders Explained

4.

Efficient Management of First line ALK-rearranged NSCLC - Part II

5.

A Comprehensive Guide to First Line Management of ALK Positive Lung Cancer - Part VIII

Fastest Growing Medical Platform for Doctors

Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801

Phone :
+1-415-463-3094

Email :
anishagadia@hidoc.co

Quick Links

Drug DatabaseDrug InteractionDiseases Database
KOL VideosKnowledge HubQuizzes
Medical UpdatesEventsAbout Us

© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
Home
Profile
Login
bot